The UK will witness an increase in Chronic Obstructive Pulmonary Disease (COPD) in the near future, with the corresponding therapy market demonstrating greater revenue growth as a result
The firm's latest report* forecasts COPD prevalence in the UK will climb from 2.3 million in 2012 to 2.8 million in 2019, while other major European countries, including Germany, France, Italy and Spain, are anticipated to experience relatively stable patient figures.
Correspondingly, the UK's COPD therapeutics market value is expected to outperform its European competitors in terms of growth, with revenue climbing from $483m in 2012 to $855m in 2019 at a Compound Annual Growth Rate (CAGR) of 8.5%.
The disease is the fifth-leading cause of death in the world is a progressive disorder associated with chronic inflammation of the airways and lungs.
The authors believe the UK's steadily rising COPD prevalence could be attributed to greater awareness and diagnosis of COPD amongst younger people. The early stages of COPD often go undiagnosed, resulting in low diagnosis rates, but this is expected to improve across the UK in the following decade.
The global COPD therapeutics market will be driven by the entry of new, more efficacious and convenient products over the coming years. Upcoming combination drugs including Novartis's QVA-149, GSK's umeclidinium bromide/vilanterol and Boehringer Ingelheim's olodaterol/tiotropium promise greater efficacy than their individual components and currently available treatments, and the continued growth of the industry will rely largely on their success.
The new report states that much of the unmet need associated with COPD can be linked to poor treatment adherence. Accordingly, current drug development programs are focusing on producing long-acting, once-daily medications that offer greater convenience over many current treatments that require more frequent dosages.
This report provides detailed analysis of the COPD pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The COPD clinical trial landscape is then analysed, with a particular emphasis on failure rates across phases as well as the trends in clinical trial size and duration and by mechanism of action.